End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.22 CNY | -2.34% |
|
-4.56% | -11.18% |
Jan. 22 | Yiling Pharmaceutical's Unit Gets Registration Certificate for Qifangbitong Tablets | MT |
Jan. 08 | Yiling Pharma Withdraws Plans to Trial Assisted Reproductive Drug | MT |
Capitalization | 23.76B 3.26B 3.12B 2.94B 2.59B 4.63B 284B 5.14B 34.94B 12.96B 118B 12.23B 11.99B 495B | P/E ratio 2024 * |
18.1x | P/E ratio 2025 * | 15.2x |
---|---|---|---|---|---|
Enterprise value | 23.15B 3.18B 3.04B 2.87B 2.52B 4.51B 276B 5.01B 34.04B 12.62B 115B 11.92B 11.68B 482B | EV / Sales 2024 * |
2.23x | EV / Sales 2025 * | 1.89x |
Free-Float |
42.61% | Yield 2024 * |
2.17% | Yield 2025 * | 2.69% |
1 day | -2.34% | ||
1 week | -4.56% | ||
Current month | +4.48% | ||
1 month | -9.71% | ||
3 months | -18.56% | ||
6 months | -16.70% | ||
Current year | -11.18% |







Manager | Title | Age | Since |
---|---|---|---|
Xiang Jun Wu
CEO | Chief Executive Officer | 50 | 2013-03-31 |
Chen Guang Li
DFI | Director of Finance/CFO | 52 | 2018-04-23 |
Qiu Lian Zhang
PRN | Corporate Officer/Principal | 55 | 2020-01-15 |
Director | Title | Age | Since |
---|---|---|---|
Yi Ling Wu
CHM | Chairman | 76 | 2012-08-30 |
Xiang Jun Wu
BRD | Director/Board Member | 50 | 2010-08-30 |
Chen Guang Li
BRD | Director/Board Member | 52 | 2018-05-16 |
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-2.34% | -4.56% | -31.47% | -40.55% | 3.35B | ||
-0.31% | +0.09% | +1.56% | +56.70% | 5.21B | ||
+1.93% | +1.53% | -3.78% | +6.18% | 3.09B | ||
-1.09% | -4.79% | +5.59% | +19.43% | 2.87B | ||
-1.12% | -0.99% | -10.98% | -25.74% | 2.23B | ||
-1.59% | -2.59% | +6.26% | -18.37% | 1.56B | ||
+1.75% | -5.09% | +6.61% | +47.85% | 1.55B | ||
-2.95% | -3.47% | -7.42% | -39.06% | 1.54B | ||
-1.12% | -3.01% | +39.57% | +53.63% | 1.36B | ||
-1.94% | -2.43% | -29.95% | -43.72% | 1.21B | ||
Average | -0.88% | -1.19% | -2.40% | +1.63% | 2.4B | |
Weighted average by Cap. | -0.72% | -0.94% | -3.82% | +7.59% |
2024 * | 2025 * | |
---|---|---|
Net sales | 10.38B 1.43B 1.36B 1.29B 1.13B 2.02B 124B 2.25B 15.27B 5.66B 51.74B 5.35B 5.24B 216B | 11.71B 1.61B 1.54B 1.45B 1.28B 2.28B 140B 2.53B 17.22B 6.39B 58.35B 6.03B 5.91B 244B |
Net income | 1.31B 180M 172M 162M 143M 256M 15.64B 283M 1.93B 715M 6.53B 675M 661M 27.32B | 1.56B 215M 205M 194M 170M 305M 18.66B 338M 2.3B 852M 7.79B 805M 789M 32.57B |
Net Debt | -610M -83.83M -80.13M -75.61M -66.45M -119M -7.28B -132M -897M -333M -3.04B -314M -308M -12.72B | -1.65B -227M -217M -205M -180M -323M -19.75B -358M -2.43B -902M -8.25B -852M -835M -34.49B |
Date | Price | Change | Volume |
---|---|---|---|
25-02-17 | 14.22 ¥ | -2.34% | 14,940,710 |
25-02-17 | 14.56 ¥ | -0.61% | 18,432,400 |
25-02-14 | 14.65 ¥ | +0.34% | 14,951,460 |
25-02-13 | 14.60 ¥ | -0.21% | 14,637,760 |
25-02-12 | 14.63 ¥ | -0.07% | 14,469,370 |
End-of-day quote Shenzhen S.E., February 17, 2025
More quotes
Annual profits - Rate of surprise
- Stock Market
- Equities
- 002603 Stock